IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
IAI.01081-06v1
75/4/1778    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Becker, P. D.
Right arrow Articles by Grinstein, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Becker, P. D.
Right arrow Articles by Grinstein, S.
Infection and Immunity, April 2007, p. 1778-1784, Vol. 75, No. 4
0019-9567/07/$08.00+0     doi:10.1128/IAI.01081-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Intranasal Vaccination with Recombinant Outer Membrane Protein CD and Adamantylamide Dipeptide as the Mucosal Adjuvant Enhances Pulmonary Clearance of Moraxella catarrhalis in an Experimental Murine Model{triangledown}

Pablo D. Becker,1,2 Gustavo M. Bertot,1 David Souss,1 Thomas Ebensen,2 Carlos A. Guzmán,2* and Saúl Grinstein1*

Virology Laboratory, Ricardo Gutiérrez Children's Hospital, Buenos Aires, Argentina,1 Department of Vaccinology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, D-38124 Braunschweig, Germany2

Received 11 July 2006/ Returned for modification 14 August 2006/ Accepted 3 November 2006

Moraxella catarrhalis causes acute otitis media in children and lower respiratory tract infections in adults and elderly. In children the presence of antibodies against the highly conserved outer membrane protein CD correlates with protection against infection, suggesting that this protein may be useful as a vaccine antigen. However, native CD is difficult to purify, and it is still unclear if recombinant CD (rCD) is a valid alternative. We performed a side-by-side comparison of the immunogenicities and efficacies of vaccine formulations containing native CD and rCD with adamantylamide dipeptide as the mucosal adjuvant. Intranasal vaccination of mice stimulated the production of high CD-specific antibody titers in sera and of secretory immunoglobulin A in mucosal lavages, which cross-recognized both antigens. While vaccination with native CD increased the number of interleukin-2 (IL-2)- and gamma interferon-producing cells, rCD mainly stimulated IL-4-secreting cells. Nevertheless, efficient bacterial clearance was observed in the lungs of challenged mice receiving native CD and in the lungs of challenged mice receiving rCD (96% and 99%, respectively). Thus, rCD is a promising candidate for incorporation in vaccine formulations for use against M. catarrhalis.


* Corresponding author. Mailing address for Carlos A. Guzmán: Department of Vaccinology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, D-38124 Braunschweig, Germany. Phone: 49 531 618 1558. Fax: 49 531 618 1411. E-mail: carlos.guzman{at}helmholtz-hzi.de. Mailing address for Saúl Grinstein: Laboratorio de Virología, Hospital de Niños Ricardo Gutiérrez, Gallo 1330, 1425 Buenos Aires, Argentina. E-mail: virologia_hnrg{at}yahoo.com.ar.

{triangledown} Published ahead of print on 13 November 2006.

Editor: D. L. Burns


Infection and Immunity, April 2007, p. 1778-1784, Vol. 75, No. 4
0019-9567/07/$08.00+0     doi:10.1128/IAI.01081-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2007 by the American Society for Microbiology. All rights reserved.